BioMarin Pharmaceutical Inc. (LON:0HNC)
London
· Delayed Price · Currency is GBP · Price in USD 58.01
-1.15 (-1.94%)
At close: Jul 11, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
NAGLAZYME | 479.58M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
NAGLAZYME Growth | 21.18% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ALDURAZYME | 183.89M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ALDURAZYME Growth | 49.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
KUVAN | 120.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
KUVAN Growth | -33.74% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
FIRDAPSE | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
FIRDAPSE Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other | 44.47M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other Growth | -7.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
VIMIZIM | 739.78M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
VIMIZIM Growth | 4.43% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
BRINEURA | 169.08M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
BRINEURA Growth | 5.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
PALYNZIQ | 355.05M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
PALYNZIQ Growth | 17.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
VOXZOGO | 735.09M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
VOXZOGO Growth | 48.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
ROCTAVIAN | 26.07M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other | 44.47M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other Growth | -7.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Royalty and Other | 44.47M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other Growth | -7.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other | 44.47M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Royalty and Other Growth | -7.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States | 924.81M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Growth | 22.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe | 829.03M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Growth | 22.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Latin America | 378.08M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Latin America Growth | 12.96% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rest of World Revenue (Pre-Q3 2024) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rest of World Revenue (Pre-Q3 2024) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 677.52M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 57.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|